R. E. Haddock
Impact in
- Pharmacology top 0.5%
- Pharmacogenetics and Drug Metabolism
- Treatment of Major Depression
- Inflammatory mediators and NSAID effects
- Toxicology top 5%
- Forensic Toxicology and Drug Analysis
Papers in
- Pharmacology 12
- Pharmacogenetics and Drug Metabolism 12
- Inflammatory mediators and NSAID effects 4
- Pharmacology and Obesity Treatment 1
-
- Drug Solubulity and Delivery Systems 1
- Co-authors
- MS Lennard (3 shared papers)GT Tucker (3 shared papers)H. Kim Crewe (2 shared papers)P. F. Langley (2 shared papers)W. H. Greb (4 shared papers)Barry D. Zussman (1 shared paper)GRAHAM MELLOWS (1 shared paper)C M Kaye (1 shared paper)
- Journals
- British Journal of Clinical Pharmacology (3 papers)Acta Psychiatrica Scandinavica (3 papers)Xenobiotica (2 papers)Journal of Pharmacy and Pharmacology (1 paper)Drugs (1 paper)
- Partner nations
- United Kingdom
In The Last Decade
R. E. Haddock
14 papers receiving 880 citations
R. E. Haddock's Hit Papers
Peers
Comparison fields: 5 of 69
- Pharmacology 547
- Pharmacology 296
- Toxicology 56
- Analytical Chemistry 50
- Geriatrics and Gerontology 15
Countries citing papers authored by R. E. Haddock
This map shows the geographic impact of R. E. Haddock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. E. Haddock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. E. Haddock more than expected).
Fields of papers citing papers by R. E. Haddock
This network shows the impact of papers produced by R. E. Haddock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. E. Haddock. The network helps show where R. E. Haddock may publish in the future.
Co-authors
The 18 scholars most cited alongside R. E. Haddock, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | The effect of selective serotonin re‐uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Hit paper breakdown → | 1992 | 421 |
| 2 | 1989 | 222 | |
| 3 | 1992 | 119 | |
| 4 | 1989 | 85 | |
| 5 | 1984 | 65 | |
| 6 | 1999 | 51 | |
| 7 | 1994 | 25 | |
| 8 | 1990 | 12 | |
| 9 | 2004 | 10 | |
| 10 | [Absent enterohepatic circulation of the active metabolite of nabumetone]. | 1988 | 8 |
| 11 | 1989 | 8 | |
| 12 | 1983 | 6 | |
| 13 | Lack of enterohepatic circulation of the active metabolite of nabumetone in humans. | 1992 | 5 |
| 14 | Kinetics of granisetron hydrochloride-distribution, metabolism and excretion in rats and dogs following intravenous administration | 1990 | 3 |
About R. E. Haddock
R. E. Haddock is a scholar working on Pharmacology, Pharmacology, Pharmaceutical Science, Pediatrics, Perinatology and Child Health and Surgery, having authored 14 papers that have together received 1k indexed citations. Recurring topics across this work include Pharmacogenetics and Drug Metabolism (12 papers), Inflammatory mediators and NSAID effects (4 papers), Pharmacology and Obesity Treatment (1 paper), Drug Solubulity and Delivery Systems (1 paper), Nausea and vomiting management (1 paper) and Pharmaceutical studies and practices (1 paper). The work is most often cited by research in Pharmacology (547 citations), Pharmacology (296 citations), Toxicology (56 citations), Analytical Chemistry (50 citations) and Geriatrics and Gerontology (15 citations). R. E. Haddock has collaborated with scholars based in United Kingdom. Frequent co-authors include MS Lennard, GT Tucker, H. Kim Crewe, P. F. Langley, W. H. Greb, Barry D. Zussman, GRAHAM MELLOWS, C M Kaye, J. C. Bloomer and D.R. Thomas. Their work appears in journals such as British Journal of Clinical Pharmacology, Acta Psychiatrica Scandinavica, Xenobiotica, Journal of Pharmacy and Pharmacology and Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.